Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

NEW YORK (TheStreet) -- Brainstorm Cell Therapeutics (BCLI) shares are up 9.13% to $5.02 as the biopharmaceutical company's stock gains momentum after the company announced that it will present positive results fromits phase 2a study of NurOwn when it releases the full set of data next weekat the American Academy of Neurology annual meeting.

The Israel-based developer of adult stem cell technologies for neurodegenerative diseases is developing NurOwn, a treatment being tested on patients with ALS or Lou Gehrig's disease, which is designed as a cell therapyin which bone marrow-derived mesenchymal stem cells are induced to secretfactors known to promote neuronal survival.

"We are thrilled to have the opportunity to share our results at this prestigious venue, and we look forward to discussing these findings with the medical community," said CEOTony Fiorino, MD, PhD. BCLI data by YCharts

Must Read: Warren Buffett's Top 25 Stocks for 2015

Link:
Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results

Related Posts